Literature DB >> 30688738

Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Gary A Ulaner1, Lisa Bodei.   

Abstract

Ga-DOTATATE is a radiolabeled somatostatin analog used for the detection and characterization of somatostatin receptor (SSR)-overexpressing tumors, particularly well-differentiated neuroendocrine tumors. We present a case of a 65-year-old man with well-differentiated pancreatic neuroendocrine tumor post-Whipple surgery and a new liver lesion on CT. Ga-DOTATATE PET/CT was performed for SSR characterization and restaging, which demonstrated the lesion to be intensely SSR positive and interpreted as a neuroendocrine metastasis. However, subsequent pathology proved the lesion to be a hepatocellular carcinoma. This case adds hepatocellular carcinoma as a potentially DOTATATE-avid malignancy to be considered in the differential diagnoses of SSR-positive liver lesions.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30688738      PMCID: PMC6687392          DOI: 10.1097/RLU.0000000000002467

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Authors:  Irene Virgolini; Valentina Ambrosini; Jamshed B Bomanji; Richard P Baum; Stefano Fanti; Michael Gabriel; Nikolaos D Papathanasiou; Giovanna Pepe; Wim Oyen; Clemens De Cristoforo; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10       Impact factor: 9.236

2.  Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.

Authors:  Ivan Borbath; Renaud Lhommel; Yves Guiot; Emmanuel Coche; Christine Sempoux
Journal:  Acta Gastroenterol Belg       Date:  2012-06       Impact factor: 1.316

3.  Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.

Authors:  Marie Lequoy; Christèle Desbois-Mouthon; Dominique Wendum; Vandana Gupta; Jean-Luc Blachon; Olivier Scatton; Sylvie Dumont; Mireille Bonnemaire; Fabien Schmidlin; Olivier Rosmorduc; Laetitia Fartoux
Journal:  Histopathology       Date:  2016-11-10       Impact factor: 5.087

4.  Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.

Authors:  G Treiber; T Wex; C Röcken; P Fostitsch; P Malfertheiner
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

Review 5.  Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies.

Authors:  Lisa Bodei; Valentina Ambrosini; Ken Herrmann; Irvin Modlin
Journal:  J Nucl Med       Date:  2017-08-17       Impact factor: 10.057

Review 6.  Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman; Angela Lamarca; Juan W Valle; Richard A Hubner
Journal:  Endocr Relat Cancer       Date:  2014-10-21       Impact factor: 5.678

7.  The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.

Authors:  Dimitrios Dimitroulopoulos; Dimitrios Xinopoulos; Klisthenis Tsamakidis; Athanassios Zisimopoulos; Efthimios Andriotis; Sofia Markidou; Demosthenes Panagiotakos; Christina Chrysohoou; Athanassios Bazinis; Emmanuel Paraskevas
Journal:  Hepatogastroenterology       Date:  2002 Sep-Oct

8.  Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study.

Authors:  Eric Nguyen-Khac; Isabelle Ollivier; Thomas Aparicio; Véronique Moullart; Alexis Hugentobler; Rachida Lebtahi; Céline Lobry; Christiane Susini; Christian Duhamel; Séverine Hommel; Jean François Cadranel; Jean-paul Joly; Jean Claude Barbare; Blaise Tramier; Jean Louis Dupas
Journal:  Cancer Biol Ther       Date:  2009-11-05       Impact factor: 4.742

  8 in total
  2 in total

Review 1.  Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.

Authors:  Vetri Sudar Jayaprakasam; Viktoriya Paroder; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2021-05-06       Impact factor: 4.802

Review 2.  Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge.

Authors:  Zhouying Peng; Yumin Wang; Ruohao Fan; Kelei Gao; Shumin Xie; Fengjun Wang; Junyi Zhang; Hua Zhang; Yuxiang He; Zhihai Xie; Weihong Jiang
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.